C-PJFVNeuroNascent Inc (NNI)
oral small molecules, neurogenesis, neuron regeneration
replacementreplacingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-PJFV
C-PJFVC-PJFVoral small molecules, neurogenesis, neuron regeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Watch the Full Video at https://www.jove.com/v/2199/growth-differentiation-adult-hippocampal-arctic-ground-squirrel?utm_source=youtube&utm_medium=social_global&utm_campaign=reseach-videos-2022. Growth and Differentiation of Adult Hippocampal Arctic Ground Squirrel Neural Stem Cells - a 2 minute Preview of the Experimental Protocol Kelly L. Drew, Rebecca C. McGee, Matthew S. Wells, Judith A. Kelleher-Andersson University of Alaska at Fairbanks, Alaska Basic Neuroscience Program, Institute of Arctic Biology; Hood College, Department Biochemistry; Neuronascent, Inc., Department of Cell Biology; Neuronascent, Inc., Research and Development; Neural stem cells were prepared from the hippocampus of adult non-hibernating yearling Arctic ground squirrels (AGS). These neural stem cells can be expanded through numerous passages, differentiated and maintained as a nearly 50:50 neuron to glial culture. Visit https://www.jove.com?utm_source=youtube&utm_medium=social_global&utm_campaign=reseach-
The purpose of this study is to examine the safety, tolerability and pharmacokinetics of single and multiple doses of NNI-362 in healthy aged population.
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science | UCB Skp to main content Main navigation Menu Innovation Innovation Overview Capabilities Innovation is Pipeline Drug discovery Clinical studies Publications You might be interested in... Page Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity Page Publications - A dedicated space where we share a collection of our scientific peer-reviewed... Page Pipeline - Check out our clinical development pipeline spanning several therapy areas Sol … Direct access to our latest annual report Story 9 Feb 2026 UCB Community Health Fund enters a new phase Page UCBCares® - Discover what UCBCares® is about and the services they offer Newsroom Newsroom Overview Press releases Our stories Resources Contact details You might be interested in... Press Release 11 Mar 2026 BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study... Press Release 26 Feb 2026 Strong Execution Fueling Sustaine
%PDF-1.7 %���� 606 0 obj > endobj 636 0 obj >/Filter/FlateDecode/ID[ ]/Index[606 74]/Info 605 0 R/Length 138/Prev 295199/Root 607 0 R/Size 680/Type/XRef/W[1 3 1]>>stream h�bbd```b``� S�l7ɮ "9��� `�%��L.� �ly` �x��f�� {@$�:��fO��+@*e�@��`����A$�#�|&��T���ՀͿ�H��)�������f��F�g`�x �|R� endstream endobj startxref 0 %%EOF 679 0 obj >stream h�b``�a``z����b��0�D8��d�����A�хM���m�9�F֥lGXsؘ�Y2���bP���0�y���#���LO����00�\#�7��v�fc`04�����RW ���@���Z endstream endobj 607 0 obj >/Metadata 7 0 R/Pages 604 0 R/StructTreeRoot 11 0 R/Type/Catalog/ViewerPreferences 637 0 R>> end … u�]�b�!��Hd�Q���݇= �Ek �eS�)G��n+/h��[�W� >stream Microsoft® PowerPoint® 2019 application/pdf Tolerance to Oxygen Glucose Deprivation in Differentiated Adult Hippocampal Neuronal Stem Cells Obtained from Arctic Ground Squirrels (Spermophilus parryii) K.L. Drew, M.S. Wells1, S.L. Christian, and J.A. Kelleher-Andersson1. Univ. of Alaska Fairbanks, Alaska Basic Neuroscience Program, Fairbanks, AK; 1Neuronascent, Inc., Clarksville, MD. Kelly Drew Microsoft® PowerPoint® 2019 202
%PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��[Yo��~ `�C#�`q�$�`�1Nf�u��!�-�#b%R)y7�>ut7�iQ�`wl�죺���.�O?���O? =I!s����)B�O�, �(Y�����!��� >~��m�2 � ��Q�K�{ �� �ptBz: u"J� R�)&bzf��[/2:�c���,��=Lg�dS�j�K{���f:�'�i2�? �mu\݈z�����t��b����^� �tD���+ ޙ�8�o�؞%A*}�FE�e��wc��jkd�H& � %�#�Sy�i k��c����c�:�w7��4�)� ��5 %tb����#� c`���`�����3ld� Y=@�zG~��ߧ��ƭ��fT+Ji����U :Ѯ@�nD�,K��L� c���?���D%X ЉEsĭqg@�j}�m
Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders | BioBuzz All Regions All Regions BioHealth Capital Region Greater Philadelphia Research Triangle Park News Events BioCatalyst Program Sign Up BioHealth Capital Region Industry Trends Press Release Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders By Sharlene Brown, PhD · Published December 3, 2019 · 7 min read · BioHealth Capital Region ← News / Why The Next Biotech Boom Could be Sparked… Several Maryland Biotech Firms Are Blazing New Trai … lle, Maryland announced the FDA clearance of its investigational new drug (IND) application for its oral glia-to-neuron conversion drug, NNI-362, in May 2019 and began placebo-controlled Phase IA trials in August 2019. The company, founded by CEO Judith Kelleher-Andersson, PhD, received $2.5M in the fall of 2018 from the National Institute on Aging (NIA) and is expected to report primary outcomes in April 2020. Howard Federoff, M.D., PhD, and faculty member at the University
%PDF-1.7 %���� 58 0 obj > endobj 82 0 obj >/Filter/FlateDecode/ID[ ]/Index[58 60]/Info 57 0 R/Length 116/Prev 197232/Root 59 0 R/Size 118/Type/XRef/W[1 3 1]>>stream h�bbd```b``6� ;@$�%��"y��H�:��8����`�,"���|���U�}!� "��$c�/�-� Dn="Y�@� {�����t�I�{� >stream h�b```c``z�������A��X��, L�� �J+v �I�\/~(��jz��!� LJ , �AHB��10=5�b@,֚� �X���'�O�q+�M&I�[|�yo�6�se��������Z�ckӁ��JF���� L/Y�43�Ø���0�>& )������ l?3C �� �� )� endstream endobj 59 0 obj >>>/Lang(en-US)/Metadata 20 0 R/Outlines 55 0 R/Pages 56 0 R/Type/Catalog/ViewerPreferences >>> endobj 60 0 obj >/ExtGSt … 7e-ffce1577d49e xmp.did:003E6668332068118A6D8319923ED728 default converted from application/x-indesign to application/pdf Adobe InDesign CC 13.1 (Macintosh) / 2018-11-28T11:57:55-06:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 21 0 obj >stream h�25S0P���w�/�+Q0���L)�63 )�Is� RY�� ���Zlg`i� endstream endobj 22 0 obj >stream h�\̱ �0��W������R �P,tptI�C�����Bqq���O��PU��l�6 ��X 퉊o�T*�]���� 1=�00�����=4 �&'����_��� !�`�����!C�r} �5���u 7D�@*G
Cytoprotection by a naturally occurring variant of ATP5G1 in Arctic ground squirrel neural progenitor cells | eLife Skip to Content eLife home page Menu Home Browse Magazine Community About Search Alerts Submit your research Search by keyword or author Reset form Search Limit my search to Cell Biology Research Article Cell Biology Genetics and Genomics Cytoprotection by a naturally occurring variant of ATP5G1 in Arctic ground squirrel neural progenitor cells Neel S Singhal Meirong Bai Evan M Lee Shuo Luo Kayleigh R Cook Dengke K Ma Department of Neurology, University of California-San F … l Medical Sciences (R01GM117461) Dengke K Ma Pew Charitable Trusts (Pew Scholar Award) Dengke K Ma David and Lucile Packard Foundation (Fellowship) Dengke K Ma Innovative Genomics Institute (Curci Scholar Award) Dengke K Ma American Heart Association (18CDA34030443) Neel S Singhal Meirong Bai American Heart Association (19POST34381071) Neel S Singhal Meirong Bai The funders had no role in study design, data collection and interpretation, or the decision to submit the work for … 34381071, respectively. DKM receives support from National Institutes of Health grant R01GM117461, Pew Scholar Award, Curci Faculty Scholar Award from the Innovative Genomics Institute, and Packard Fellowship in Science and Engineering. We thank Dr. Judith Kelleher of Neuronascent for AGS NPCs and acknowledge use of sponsored core facilities including the UCSF Laboratory for Cell Analysis (P30CA082103) and the Histology and Light Microscopy Core at the Gladstone Institutes. C … ine Community About Research categories Inside eLife Search Subscribe to alerts Submit your research Author guide Reviewer guide Back to top About Jobs Who we work with Alerts Contact Terms and conditions Privacy notice Inside eLife Monthly archive For the press Resources XML and Data Find us on GitHub eLife is a non-profit organisation advancing open science by transforming how research is communicated, reviewed, and assessed. By developing open tools and collaborating with
%PDF-1.7 %���� 1 0 obj >/Metadata 82 0 R/ViewerPreferences 83 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 11 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��=ko 7�� �?�G�b��|��H�8� ��پ��}Ic�{�X���� �l�&��p�������b�����շ�~�������ϟ��x��mZ�7 �jW��ڏr�y�������?}����O�y!VB�{�D��+��FJ��j�~���Џ�����}��ܽ�W?>}����z� �n�u�y��.�y��/۫S��[ �߸^����ߞ>����O ��T�e:�&|VlP�F�P^�U��`] ����� ~�.�lځ�@= ��/+ ��z8�~�1�W�4� �����_��vg�Ȼ�^{������Cc�M�( �~�� x��=��cZ��]3�+����G
Neuronascent Awarded $2.25 Million NIH Grant to Develop a Regenerative Therapeutic for Alzheimer’s Disease | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Neuronascent lands NIA grant to advance Alzheimer’s treatment to Phase 2 clinical trials Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Diam … raises $12... Biotech Investment Investment Aug 24, 2023 Neuronascent lands NIA grant to advance Alzheimer’s treatment to Phase 2 clinical trials LT Staff Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: Email ... or meeting booking link Neuron regeneration company Neuronascent has been granted a U01 award by the National Institute of Aging (NIA) to advan … 362, into Phase 2 clinical trials for mild to moderate Alzheimer’s disease. The grant will enable Neuronascent to conduct long-term safety testing and GMP manufacture of NNI-362. The testing is essential before proceeding with a trial to assess if NNI-362 can halt and potentially reverse the disease’s progression, improving memory and executive function in patients. “There is still a need for therapies to actually halt and potentially reverse the disease at the next sta … ghlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency You might also like Scribe lands $25m to advance heart disease gene therapies ŌURA-LillyDirect collab highlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency Peers Capital bets on prevention before the pivot NorthStrive eyes emerging GLP-1 opportunity: muscle preservation LT Staff Longevity.Technology's in-house writing staff. Sign up for our dail
%PDF-1.5 %���� 21 0 obj > endobj 42 0 obj >/Filter/FlateDecode/ID[ ]/Index[21 45]/Info 20 0 R/Length 99/Prev 92312/Root 22 0 R/Size 66/Type/XRef/W[1 2 1]>>stream h�bbd``b`:$@�} �. $8RA� >stream h�b```c``�f`a`:� Ȁ�@1V �0��� �\�fz������ ��2@��� ���X,r�A���͋}�i6 �j6 �{ >�S872�`�d�b?������0�8���4#�.nƴ5>#/@�4 endstream endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj >stream hX�n�~��Ο�tĻb'٤� k�i��bӱ�ʒ+ɻI��3�|�&�mq � �Ù!9���J��)ń�Li&�d�0a S�I!�����I�+b���iδ6L +��d\ ˴b\�4�xb�i��E�R1 3��O��&a�"5�6�Ik53��ˈ�A �W�]p���/��ӑ�Nm��}@2&����H ��S�~Ф �� p� � � RҦ�hca … E����DVDBG8� � �2!�̐f0����dD0�#~t�p�o�'��;��B�� 1B>6B>2D >stream application/postscript bioworld3 Adobe Illustrator CS4 2011-10-19T14:41:04-04:00 2011-10-19T14:41:05-04:00 2011-10-19T14:41:05-04:00 256 48 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8f … 08082168118A6DA88DDA86292E uuid:0EF781CED9A2DE118B329347B5ADBC07 converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:04801174072068118A6DA88DDA86292E 2011-10-17T11:00:36-04:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:149A3A5874FAE011B413AA70F4B496E6 2011-10-19T13:18:43-04:00 Adobe Illustrator CS4 / converted from application/postscript to application/vnd.adobe.illustra … 6DA88DDA86292E 2011-10-19T14:35:26-04:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:DA8FECE681FAE0118CBFFF5933633139 2011-10-19T14:41:05-04:00 Adobe Illustrator CS4 / uuid:0EF781CED9A2DE118B329347B5ADBC07 Print 792.000000 612.000000 Points 1 False True Cyan Magenta Yellow Black PANTONE 2738 C Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Black CMYK PROCESS 0.000000 0.000000 0 … PScript5.dll Version 5.2.2 2012-09-21T15:35:50-04:00 2012-09-21T15:35:50-04:00 application/pdf BWT 091312 NeuroNascent.indd robert.kimball Acrobat Distiller 9.5.2 (Windows) uuid:606c93e6-697c-452c-98ee-2b4e590eb82a uuid:6a2af1cf-e557-4c6a-9972-0baece32955a endstream endobj 10 0 obj >stream h�2�T0P���w�/�+Q0���L)�62 )��X��ʂT�����b;;�%D � ends
%PDF-1.6 %���� 6679 0 obj > endobj 6696 0 obj >/Filter/FlateDecode/ID[ ]/Index[6679 27]/Info 6678 0 R/Length 84/Prev 4268950/Root 6680 0 R/Size 6706/Type/XRef/W[1 2 1]>>stream h�bbd``b`Q ӁS�`�OA�^��⦂X� V �e "� 7�$Q $��001J-��H�����O�@ - endstream endobj startxref 0 %%EOF 6705 0 obj >stream h�b```e``�f`a`��� ̀� �@9��)&.ʊ"' ���6;��(�(+ ) ) L�������Lsy"�[�:4�U$�%,�i����DcZ�%�e*��^����NLR�9���f�t[��V�|[ �m�U�u�%�g8�;�Dr� ة,o=�����G�T�U9�~R�?��b�^��&� ��� �3��o:�2Fʢab�˶���n�N �t[3�]����o E ��� [D$ [ ,�X"+c��W6- e�CZ �=XBc >/Metadata 521 0 R/Outlines 781 0 R … 4:11:13-04:00 2011-04-27T14:11:13-04:00 Adobe Acrobat 9.0 Paper Capture Plug-in application/pdf uuid:dd5974f3-c979-4e12-b69a-bcdb1f085074 uuid:0b76b9b4-7a47-4fa4-bf3b-518f57381e61 endstream endobj 458 0 obj >stream 2011-04-27T14:07:52-04:00 FUJITSU fi-5750Cdj 2011-04-27T14:08:12-04:00 2011-04-27T14:08:12-04:00 Adobe Acrobat 9.0 Paper Capture Plug-in application/pdf uuid:6a43411d-22cf-4487-9113-2406a64c0480 uuid:9b56ce4f-d15a-454f-9f22-cdea34614362 endstream endobj 459 0 obj > … 4:07:37-04:00 2011-04-27T14:07:37-04:00 Adobe Acrobat 9.0 Paper Capture Plug-in application/pdf uuid:9c9568ff-b5bd-4ab9-abb6-f4a99b468aad uuid:6e155a28-5b38-4cef-97e0-d1db16303ad3 endstream endobj 460 0 obj >stream 2011-04-27T14:05:45-04:00 FUJITSU fi-5750Cdj 2011-04-27T14:06:07-04:00 2011-04-27T14:06:07-04:00 Adobe Acrobat 9.0 Paper Capture Plug-in application/pdf uuid:03592b34-660c-43a4-a943-c4610c133142 uuid:c4db9c22-7fe8-4f4f-b8b2-0aaf095d3ecf endstream endobj 461 0 obj > … 4:05:33-04:00 2011-04-27T14:05:33-04:00 Adobe Acrobat 9.0 Paper Capture Plug-in application/pdf uuid:0927a305-bade-4028-b480-36b00fc7db50 uuid:f4a21605-b4bc-41dc-9c24-ce24cb77461b endstream endobj 462 0 obj >stream h�ԛ[�\����J�%A` ����0��7�c;+D�Ӡ�[cG E����[������h�v l��)��*��=�Ү���T�ߺs��jo;�e��w��u�R H�$�9 �T�����X@y@y�(�4F��1� ���F�!�Fi1B�j%�A���u�h�4Z��2ht���^cf 9I � �] Yb��i@cU�n�kk��AC�F��k�9;� -֣E �4 d:�y@�����o�~�廫��[�v���p������ۛ�?\_ n�ݟ�z … 52-04:00 2011-04-27T14:11:52-04:00 2011-04-27T14:11:52-04:00 FUJITSU fi-5750Cdj application/pdf uuid:264c3012-5d79-471f-b1a9-f78cdbd524b3 uuid:c95c393a-c029-46c4-9c8f-d520d5c0ba92 Adobe Acrobat 9.0 Paper Capture Plug-in endstream endobj 522 0 obj >stream hޜ��N1 E�0�#v"UݰdSU��JT� ��$v���H3����ǣ�h{@J�ȵ�$�E�.,�P_c� �\�L����v�e(�mB��i�$
Technology - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Technology Neurogenesis & Neuron Regeneration Drug Discovery Intellectual Property © 2026 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark Home About Us ▼ Founder’s Message Management Team Directors and Advisors Collaborators Memberships Technology ▼ Neurogenesis & Neuron Regeneration Drug Discovery Intellectual Property R&D Programs ▼ Pipeline Alzheimer’s Disease Parkinson’s Disease Developmental Delay Veterinary Medicine Program News & Events Contac
2008 Mid-Atlantic Bio Exhibitor Profiles - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital 2008 Mid-Atlantic Bio Exhibitor Profiles October 21, 2008 | 1 min read Twitter LinkedIn Facebook Email Print CHANTILLY, Va.--(BUSINESS WIRE)--The 2008 Mid-Atlantic Bio takes place October 22, 2008 - October 24, 2008 at the Westfields Marriott Washington Dulles in Chantilly. Listed below are the 2008 Mid-Atlan … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Digital RESI JPM 2022 – RESI Conference Skip to content Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs Program Guides Photo Albums Registration RESI San Diego (June) RESI Boston (Sept) Search for: Partnering Session RESI San Diego Investor Panels RESI San Diego Workshops Pitch Pitch Challenge Presenting Companies Pitch Judges Attendees Investors – RESI San Diego 2026 Exhibition Sponsors Contact Us Past RESIs Pr … cross functionally capable. Recipient of Boehringer Ingelheim’s President Award. Extensive experience covering business development, alliance management, partnering and licensing activities in diagnostics, personalized medicine, therapeutics, and technology platforms with proven track record from Boehringer Ingelheim, Massbio, Genzyme Genetics, Millennium Pharmaceuticals..Possess strong business acumen, critical thinking, negotiations and sophisticated quantitative tool … rass Roots Innovation programs – BI Office Hours, BI Academy, and BI Innovation Prize. Additionally, founded Massbio’s Pharma Days and MassConnect, a start-up mentoring service. Additionally, founded PharmaDays, a MassBio partnering service connecting major pharmaceutical companies with biotechnology and the academic community for one-on-one partnering.Industrial Expertise: Intrapreneurship, search & evaluation, business development, licensing, negotiation, transactions, … ance and entrepreneurship from Boston College. Lu Zhang Managing Partner Fusion Fund Lu Zhang, Founder and Managing Partner of Fusion Fund, is a renowned Silicon Valley investor, a serial entrepreneur and a Stanford Engineering alumna. Lu is a World Economic Forum Young Global Leader (Class of 2018). She has also garnered other accolades including the Featured Honoree in VC category of Forbes 30 under 30 (2017), Silicon Valley Women of Influence (2018), Top 10 All America Chi … male Early-Stage Investor by Business Insider in 2021. Prior to starting Fusion Fund, she was the Founder and CEO of a medical device company focused on non-invasive technology for the early diagnosis of Type II diabetes (acquired in 2012). Lu is a frequent speaker at tech events and conferences and also serves as a mentor and advisor to several
%PDF-1.6 %���� 41840 0 obj > endobj 41863 0 obj >/Filter/FlateDecode/ID[ ]/Index[41840 36]/Info 41839 0 R/Length 115/Prev 2042475/Root 41841 0 R/Size 41876/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� �@$S5XDD2���`Y�} �� ��b��'����jԀ$��p�H+� b�7�H G�� R� lr"HMH�߳ L� ���]��H&��!~�7���c endstream endobj startxref 0 %%EOF 41875 0 obj >stream h�b```�� �@җA���X��c���T&��i�� aN�~(Gr `J �Y#��ÈI�`��r� �_@���z�&��8�B�;����hrT6�L����SBo��CNw���&�H�(�x��"*8ÙLz�q�� �{0�E��!&_�Y/��r w�}лG�%g�S�@��^�EL� �ETVp� >/Metadata 673 0 R/PageLayout/OneColumn/Pages 41807 0 R/StructTreeR … �l\�Y_K���S�� �r+�'5`E�i�}Vt�j���9 ��93���-�*����rN�E�)&���tl�`w��9qlx���$rfP���^����|�}� ��>� �3�dž��$��30��\'�ze=W���(�OF�/��c��q s���?g,ɟ��E�g�L18�(����8&pvd��cN ^;���O� y�N`�bpRXt %݇E�QL�̼�3t��8C��O�yJ&0s�����(�>,��� Lw��Ӝ���I��yJ&0s����0�>*�� ���9� ̜�$r���c2�����݇I�q�}pL�;o�� ��͒7��1w͟�����b@RRt $�'E��1�o���4'�7��$rF{�O&�s����F�}Rt�8&�7���2do`�I�����j�] endstream endobj 529 0 obj >stream hތW��\7 }/�E�X�!PH��R>�� �tQ��T����j�l … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:d5c954ed-4e63-4120-9c4e-4fee49bb2d27 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 674 0 obj >stream hޜ��n1�_��`�����\8r�"n�C$"� � �U���ha|����s��*w����]��M��7�A,A��CY��\RC5J�XM�96KI��H���J3|��� U-tY}H��i��Ӑ.�i �(� �D�aX�a�e�� �ˆ)�ley���8���4fsS ���,�G1���$u��?�F9���>���8��������_�^{�zz����G,m�G�U����T���>�>���|zx���r��� … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:197d980b-d491-4ad6-9ce6-c98f78fcfff2 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 41842 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 41876 0 obj > endobj 41877 0 obj >stream H���mo����S�B �VK.�@� ���; ���"+���JJ.�� �W�Ȍ�&H$�,9�?��ο� 6���C������a��Y_ ��C����l���P� �����jQ� … 457686-005c-499b-acd6-ffd3f7e43af1 uuid:38a70a0c-3e84-4398-a1b1-6e1d89d8496a 68 application/pdf Nicole Reisinger Adobe PDF Library 20.9.95 D:20200507 D:20200514 0x010100307CA6F60A88184B9EB3E10E019544DC endstream endobj 41842 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 41887 0 obj > endob
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
2008 Mid-Atlantic Bio Exhibitor Profiles Anzeige ❌ Mehr » Ad hoc-Mitteilungen : Samstag, 27.06.2026 - Börsentäglich über 12.000 News Brasiliens Moment für seltene Erden ist gekommen Anzeige Indizes Kurs % News 24 h / 7 T Aufrufe 7 Tage Aktien Kurs % News 24 h / 7 T Aufrufe 7 Tage Xetra-Orderbuch Fonds Kurs % Devisen Kurs % Rohstoffe Kurs % Themen Kurs % Erweiterte Suche Startseite Nachrichten Nachrichten Nachrichten auf FN Alle News Rubriken Aktien im Blickpunkt Ad hoc-Mitteilungen Bestbewertete News Meistgelesene News Konjunktur- und Wirtschaftsnews Marktberichte Empfehlungsübersi
CNS Conference | CNS Conferences | Cognitive Neuroscience Conferences | CME Conference | Europe Meetings | USA | Middle East | 2017 | Asia | Australia --> --> --> --> 3 rd International Conference on Central Nervous System Disorders & Therapeutics Oct 02-03, 2017 Vienna, Austria Organizing Committee Submit Abstract Register Now Scientific Program --> Recommended Global Neuroscience Conferences USA & Americas American Dental Congress 2026, USA Annual Cardiology 2026, Canada Annual Mental Health 2026, Canada Europe & Middle East EURO MENTAL DISORDER 2027, France Stroke Meeting 2027, Fran
Onyx Completes API project with Neuronascent ✕ Home Pharma Manufacturing News + Pharmaceutical Insights + Pharma Manufacturing Resources + Subscribe Talk to us | Media Portfolio | Latest Issue | My Account ☰ Onyx Completes API project with Neuronascent 7 May 2014 14:07 UK-based CMO Onyx Scientific has completed an API development and manufacturing project with US-based Neuronascent, Inc, a company that develops orally available neurogenic and neurorestorative therapeutics that target Parkinson’s disease, Down syndrome, Alzheimer’s disease and post-traumatic stress disorder. Neurona … ronascent and were able to deliver their project on time despite a pretty tight deadline. “We look forward to potentially having the opportunity to work with them on the next phase of the project, which would involve the GMP production of API to support clinical trials.” Onyx Scientific’s UK-based labs deal with challenging chemistry to deliver early stage programmes and is then able to scale-up, tech transfer and increase project efficiency using its
NNI-362 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 18 Apr 2026 NNI-362 Last update 18 Apr 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms NNI 362 Target NGFB Action stimulants Mechanism NGFB stimulants(Beta-nerve growth factor stimulants) Therapeutic Areas Nervous System Diseases Congenital Disorders Other Diseases Active Indication Huntington Disease Inactive Indication Alzheimer Disease Ori … sociated with NNI-362 22 Aug 2023 · www.biospace.com Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investiga … th the CEO, Dr. Judith Kelleher-Andersson being the principal investigator. The grant, titled “Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial,” will allow for the longer-term assessment of Neuronascent’s investigational drug, in a proof-of-concept clinical trial. Neuronascent discovered experimental therapeutic NNI-362 through a novel screening program aimed at identifying small … te short term GLP safety testing for submission of the Investigational New Drug application, and secondly for the completion of the Phase 1a clinical safety trial in healthy aged population. Alzheimer’s is a disease of aging, the greatest risk-factor, and even with new therapies aimed at slowing early progression into Alzheimer’s disease, there remains a great unmet need for a disease-modifying treatment for the 6.7 million patients, in the United States alone, already suffer … isease at the next stage of disease progression from pre-AD to severe AD.” This grant award should allow the further long-term safety testing and further GMP manufacture of NNI-362 required before running a critical trial to assess whether NNI-362 will indeed address the next stage of AD disease progression by halting and potentially reversing di
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
%PDF-1.5 %���� 162 0 obj > endobj 185 0 obj >/Filter/FlateDecode/ID[ ]/Index[162 64]/Info 161 0 R/Length 113/Prev 380930/Root 163 0 R/Size 226/Type/XRef/W[1 3 1]>>stream h�bbd```b``� � �i3�d��,��"�`5L �Q̾&��@$� ���k �d��b���o@d��+���� l�&��}�3�=�`�00s�?S�-�z� endstream endobj startxref 0 %%EOF 225 0 obj >stream h�b```�� � ��@����9f0l��`�(��H0��}hz� �FGCGSGL �B1�� �kc%��� |�S��e�2*hxo��{��ΐ=[1( sv`vy�����m �m��r2��� �w ��$o endstream endobj 163 0 obj >/Metadata 7 0 R/Pages 160 0 R/StructTreeRoot 11 0 R/Type/Catalog>> endobj 164 0 obj >/MediaBox[ … 9��R������ >stream hޜ��n1�_�o��_�R�A����t� �B����z� ��2.����xf| >stream application/pdf James Hendrix 2017-02-07T18:54:17-06:00 Microsoft® Word 2010 2017-02-08T09:58:06-06:00 2017-02-08T09:58:06-06:00 Microsoft® Word 2010 uuid:ef1298cb-6a17-462e-a670-e4ba8b1b3be0 uuid:27f7b6bb-df32-49cf-8a36-abf2dfab0dbc endstream endobj 8 0 obj >stream h�243P0P���w�/�+Q0���L)�643�)�Ic� RY�� ���Zlg`�n endstream endobj 9 0 obj >stream h�243T0P���w,-��/��J�M-V�H�K)ʬ��w.JM,���sI
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj >stream springer.com springerlink.com springer.com springerlink.com endstream endobj 3 0 obj >/PageTransformationMatrixList >/PageUIDList >/PageWidthList >>>>>/Resources 7 0 R/Rotate 0/StructParents 0/Thumb 8 0 R/TrimBox[0.0 0.0 595.276 793.701]/Type/Page>> endobj 4 0 obj [9 0 R 10 0 R 11 0 R 12 0 R 13 0 R 14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R 22 0 R] endobj 7 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text]/XObject >>> endobj 5 0 obj >stream x��]ms�F����g_RT�40x���*�v�m}o݇u�! �")E�3���{�{z�� �Q�[�%��tO��O����������𗿼����WO���~��� … 6-08-31T12:08:03+01:00 1 100.000000 100.000000 Pixels Cyan Magenta Yellow Black application/postscript Rakesh Masih CROSSMARK_BW_txt_100x100.eps endstream endobj 2037 0 obj > endobj 2062 0 obj >stream H��P���#�Sڥ�=hOEJC�1�ߺ���5�����q��t]{o�M�\oן����*/��,��� > endobj 2038 0 obj > endobj 2064 0 obj > endobj 2065 0 obj > endobj 2066 0 obj > endobj 2067 0 obj >stream application/pdf BMC Logo PSD_Purple 2017-05-09T16:33:13+01:00 2017-05-09T16:33:13+01:00 2017-05-09T16:14:28+
%PDF-1.6 %���� 6694 0 obj > endobj 6709 0 obj >/Filter/FlateDecode/ID[ ]/Index[6694 39]/Info 6693 0 R/Length 90/Prev 6253663/Root 6695 0 R/Size 6733/Type/XRef/W[1 3 1]>>stream h�bbd```b``="��A$� �d��������G�j���~��� R2,� $e� � >stream h��T_h[U��so��j�t�]�m.��$e2KȺl�ڤV�l�����!NevH�mȜrꔝ�+�����"U뺩/� ���E�AX�^��ҡ��E���*�����s������p> �NA�:�bsl%��D�\L@�AS�Ξ�4�� � � m�צ�r��J��6r�5�|�|��?���hY� ϲa���5Y� ��K�1i�� �ǗqR�+a���Id뗤�?11�3Y��{����Ȧ�|��9�ۿķY�K0�������z U���Ѡ�h� ۽xT����DzҖ�6;��/�� i�$3���"���Fjsa���� &���� ��i� �JO��+h]îi�xe WV�7E}�sٶ�� ��M�;��3���} … /�3$���3^Pv:�P�=��$h�a�$8]P�T�B�Q�� HJ���;�6D� �GA!��C��2 ܣ��E� ��RFP '�}`�RS|ķ����Y����p/�qxh`�뚔�1����+������ʪѰjfw =/ ĒB*-���餀�@��&� �x X@� ခ�_�ngQD@>�t~��h�f_������j����� ��շ���w��f��V�P�F��BV���x O�vzo;�K��^�ұ> �mQ�4�a{}�F#�A%��)�CY1���,���`տ���Uх�v�H9�@���� �Y�&��D'SɫUì՛m��� 6I4�\Cص� czq�� 7 ��Lzc�1���[�?lm���2L�|v}su�e��+b��������n��,��b�� ����7g���I[���� f����bB�j٣/����4L y�g# ��H,%W����us\��v�0�n5 b�"!NRaq�/� H7RƠ� … 4ce5db1-8a61-4bdd-9642-a254ff507c84 uuid:4f236239-9f36-4525-bf8a-bb19866b7b76 6 application/pdf Evaluation of the Biotechnology Investment Incentive Tax Credit An evaluation of the Biotechnology Investment Incentive Tax Credit. Maryland General Assembly biotechnology investment incentive tax credit tax credit evalution committee Adobe PDF Library 15.0 "biotechnology investment incentive tax credit"; "tax credit evalution committee" D:20181005140224 mga endstream endobj 500 0
%PDF-1.7 %���� 294 0 obj > endobj xref 294 105 0000000016 00000 n 0000003303 00000 n 0000003505 00000 n 0000003541 00000 n 0000004263 00000 n 0000004346 00000 n 0000004480 00000 n 0000004614 00000 n 0000004748 00000 n 0000004881 00000 n 0000005015 00000 n 0000005148 00000 n 0000005281 00000 n 0000005416 00000 n 0000005866 00000 n 0000006295 00000 n 0000006754 00000 n 0000007069 00000 n 0000007608 00000 n 0000007887 00000 n 0000008290 00000 n 0000008800 00000 n 0000009361 00000 n 0000009475 00000 n 0000009843 00000 n 0000012235 00000 n 0000014491 00000 n 0000014913 00000 n 0000015468 00000 n 00 … � �9�ͥ���$��nց�n�뺭s��\�Zr8�)����k{�� �rԱ endstream endobj 367 0 obj >stream application/postscript CHI 25th k Thomas Norton 2016-10-13T09:10:38-04:00 2016-10-13T09:10:38-04:00 2016-10-13T09:10:38-04:00 Adobe Illustrator CC 2015.3 (Windows) xmp.iid:3e843b59-6124-8048-b358-fa836b4c900a xmp.did:3e843b59-6124-8048-b358-fa836b4c900a uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:223536db-1da4-7647-96e0-dfe89d658647 xmp.did:223536db-1da4-7647-96e0-dfe89d658647 uuid:5D2 … 016-10-06T07:55:11-04:00 Adobe Illustrator CC 2015.3 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:3e843b59-6124-8048-b358-fa836b4c900a 2016-10-13T09:10:38-04:00 Adobe Illustrator CC 2015.3 (Windows) / Print False False 1 145.000000 70.500000 Points Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Black CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 CMYK Red CMYK PROCESS 0.000000 100.00000 … +l�{���QKV��d���7k���hٻ�e� Fm��e�9�0�UV�����]\��[���[�Skƙ �%�V� >stream application/postscript Print Thomas Norton 2016-10-31T13:44:22-04:00 2016-10-31T13:44:22-04:00 2016-10-31T13:44:22-04:00 Adobe Illustrator CC 2015.3 (Windows) xmp.iid:f0315055-5a2a-ec41-9a0f-5eaceba21ebb xmp.did:f0315055-5a2a-ec41-9a0f-5eaceba21ebb uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:a9d251e7-0e8d-43bb-a370-a9d4525d7a55 xmp.did:64fc61c4-004b-1447-a1c8-2b3443e686d3 uuid:5D20892493B … 0 Adobe PDF library 10.01 endstream endobj 372 0 obj > endobj 373 0 obj >stream application/postscript Graphics logo.eps Adobe Illustrator CS2 2007-07-31T16:46:26-04:00 2007-07-31T16:46:26-04:00 2007-07-31T16:46:26-04:00 uuid:809540DC9E3FDC11B8B697E7D3A101F2 uuid:819540DC9E3FDC11B8B697E7D3A101F2 uuid:7F9540DC9E3FDC11B8B697E7D3A101F2 uuid:7E9540DC
Neuronascent Announces the Expansion of its Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Market Research Reports and Consulting – Global Insight Services Alzheimer's Disease - Drug Pipeline Landscape, 2023 US: +1-833-761-1700 [email protected] Submit Queries Home Reports Automotive & Transportation Chemicals & Materials Consumer Goods Energy & Natural Resources Food & Beverages Manufacturing & Construction Medical Devices Pharmaceuticals Semiconductors & Electronics Technology, Media, & Telecom Services Syndicated Reports Custom reports Consulting Services Subscriptions Insights Analyst Insights Press Releases Contact Us --> Hom … gh primary sources, allowing for an overall market value to be derived for each application. Year-over-year (Y-o-Y) growth rates were applied to forecast market values for each application, reflecting a trend of slow, steady, or growing demand based on actual growth rates in each sector. The compound annual growth rate (CAGR) was calculated by analyzing industry penetration, supply and demand trends, and end-user industries' needs for the market. The market was further verifi … ted based on secondary research, including splits by battery voltage, type, and application. The demand from companies in different application segments was analyzed to assess overall market trends. Ongoing and upcoming projects implementing the market were tracked, and these insights were used to estimate market size based on key developments. Several discussions with industry leaders were conducted to validate the split of market segments by voltage, type, and application.
Press Release Distribution and Management Accessibility: Skip TopNav Latest News and Press Releases Want to stay updated on the latest news? Sign into Reader Account Create Reader Account August 13, 2025 06:00 ET | Source: Neuronascent, Inc. Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the Phase 1a trial in a … ugust 22, 2023 06:00 ET | Source: Neuronascent, Inc. Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has... June 28, 2023 06:00 ET | Source: Neuronascent, Inc. Neuronascent to Present New Parkinson’s Model Data at A … :00 ET | Source: Neuronascent, Inc. Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease CLARKSVILLE, Md., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has... Next Page
%PDF-1.6 %���� 455 0 obj > endobj xref 455 14 0000000016 00000 n 0000002005 00000 n 0000002089 00000 n 0000002222 00000 n 0000002348 00000 n 0000003076 00000 n 0000003112 00000 n 0000003189 00000 n 0000003417 00000 n 0000004144 00000 n 0000004924 00000 n 0000005171 00000 n 0000007841 00000 n 0000000576 00000 n trailer ]>> startxref 0 %%EOF 468 0 obj >stream x��V}lSU?�������k�s+]!�dB�N���@7�� �c.'�! �ƀF���n|4� C@� ��c � �U lQ4�F�Q�}�m��ϛ��; �s�����@Av�L_&��"~�N�=m��* �N���K1�cj�*�F�dc& ���'�m�V��5�V��J�^R>@��v��B�' c�d��{��-c�_ =`�m���%Y�t�z̺� uֲ�W��4rM vQZO.�h�I75�7� … PScript5.dll Version 5.2.2 2009-12-23T10:30:58+01:00 2009-12-23T10:30:58+01:00 application/pdf u030066 Microsoft Word - Masterarbeit.doc uuid:e3ca8656-4fd7-42d4-8687-7a05ce640eb7 uuid:456527c5-22f9-4be9-aeb4-1677c662a45d endstream endobj 454 0 obj > endobj xref 0 455 0000000000 65535 f 0000043269 00000 n 0000043396 00000 n 0000043508 00000 n 0000043823 00000 n 0000043950 00000 n 0000044074 00000 n 0000044465 00000 n 0000044592 00000 n 0000044716 00000 n 0000046183 00000 n 00
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier League Football Formula 1 Rugby Cri … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,508.02 -21.87 -0.21% GBP/USD 1.3198 +0.0001 +0.00% GBP/EUR 1.1589 -0.0008 -0.07% FTSE 250 23,147.19 -14.22 -0.06% AIM 770.35 -1.57 -0.20% GOLD FUTURES 4,096.30 +48.70 +1.20% ADVERTIS … ess release distributor directly with any enquiries. Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease Neuronascent, Inc. 22 August 2023 3 min read Neuronascent, Inc. ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has awarded a U01 grant to Neuronascent, with the … th the CEO, Dr. Judith Kelleher-Andersson being the principal investigator. The grant, titled "Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial," will allow for the longer-term assessment of Neuronascent's investigational drug, in a proof-of-concept clinical trial. Neuronascent discovered experimental therapeutic NNI-362 through a novel screening program aimed at identifying small … te short term GLP safety testing for submission of the Investigational New Drug application, and secondly for the completion of the Phase 1a clinical safety trial in healthy aged population. Alzheimer's is a disease of aging, the greatest risk-factor, and even with new therapies aimed at slowing early progression into Alzheimer's disease, there r
NNI-362 Lowers Alzheimer's Biomarker in Older, Healthy Adults Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About Alzheimer's disease Toggle menu: About Alzheimer's disease What is Alzheimer’s disease? Causes Symptoms Diagnosis Pseudobulbar affect Early-onset Alzheimer's Treatments Approved treatments Experimental treatments Non-drug treatments Deep brain stimulation Repetitive transcranial magnetic stimulation Living With Toggle menu: Living With Living with Alzheimer’s disease Community Toggle menu: Community Columns Treading Dark Waters — Ray … apeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease. Tags clinical trial p-tau181 Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment Recent Posts Awareness m
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
%PDF-1.5 %���� 58 0 obj > endobj 85 0 obj >/Filter/FlateDecode/ID[ ]/Index[58 81]/Info 57 0 R/Length 129/Prev 384099/Root 59 0 R/Size 139/Type/XRef/W[1 3 1]>>stream h�bbd```b``V� �I Dr���I7�zL^�7���l� >stream h�b``�d``�����z�)*`b�d1I(f`Tcd�b�cpuPb�����=���!C���6g��-����i�600��� �.'�����'�@laч����zk��{��� endstream endobj 59 0 obj >/Metadata 2 0 R/Pages 56 0 R/StructTreeRoot 6 0 R/Type/Catalog>> endobj 60 0 obj >/MediaBox[0 0 612 792]/Parent 56 0 R/Resources >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj … �qtU.��{ϳ�8+��o60� ��$�h ̟M$�|X�>���N�`�� endstream endobj 2 0 obj >stream application/pdf Brenda Shelton 2019-12-27T15:25:08-08:00 Microsoft® Word 2010 2020-02-13T17:20:51-08:00 2020-02-13T17:20:51-08:00 Microsoft® Word 2010 uuid:26b1e1d9-4bb6-47a9-b737-8e0efa76de3d uuid:01afae13-aa55-4f44-8bdd-b2e43d069896 endstream endobj 3 0 obj >stream h�25S0P���w�/�+Q0���L)�63 ��T��$�����f � endstream endobj 4 0 obj >stream h�t˱ �0�_�M J�"B��P��9���5���X����=��i�m͓h�iL��
NeuroNascent, Inc. Receives State and Federal Funding for Its Neurogenesis Therapeutic Programs - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital NeuroNascent, Inc. Receives State and Federal Funding for Its Neurogenesis Therapeutic Programs June 3, 2011 | 2 min read Twitter LinkedIn Facebook Email Print CLARKSVILLE, MD--(Marketwire - June 02, 2011) - Highlighted Links Neuronascent, Inc. Neuronascent, Inc . announced today that the Company has r … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Access Denied Access Denied You don't have permission to access "http://www.businesswire.com/AK_PM_VPATH1/714432/bw_maintenance.html" on this server. Reference #18.11c41402.1782541963.182f1090 https://errors.edgesuite.net/18.11c41402.1782541963.182f1090
NNI-351 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 NNI-351 Last update 08 May 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms - Target DYRK x NGF Action inhibitors, stimulants Mechanism DYRK inhibitors(DYRK kinase inhibitors), NGF stimulants(Nerve growth factor stimulants) Therapeutic Areas Nervous System Diseases Congenital Disorders Other Diseases Active Indication - Inactive In … ed subjects. This placebo-controlled, randomized trial was fully supported by a grant from the National Institute on Aging (NIA, part of the National Institutes of Health). In topline results, NNI-362, administered from 10 to 240 milligrams orally, once daily, showed no serious adverse events and no dose-dependent adverse events. Alzheimer’s is a disease of aging, the greatest risk-factor, but there is not a single therapy available to halt or reverse this chronic neurodegene … sorders. The research reported in this press release was supported by NIA under award number R01AG056561. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About NNI-362 In aging patients, endogenous neuron regeneration is diminished. This diminution is exacerbated in patients suffering from neurodegeneration (for example, Alzheimer’s patients). NNI-362, Neuronascent’s lead, pate … ehavioral deficits in young and young adults with Fragile X Syndrome. Marketing application for NNI-351 is required prior to receiving FDA-initiated benefits from these dual designations. The Orphan Drug Designation benefits could include exemptions from user fees and the addition of seven-years of market exclusivity. The Rare Pediatric Drug Designation could provide a valuable Priority Review Voucher that could be used by Neuronascent or sold to a pharmaceutical company. “Bo … r incentive for collaborations aimed at completing the Investigational New Drug Application and clinical stage evaluations of NNI-351 to effectively treat this developmental disorder,” said founder and CEO, Judith Kelleher-Andersson, PhD. About NNI-351 NNI-351 is Neuronascent’s lead, patented, new chemical entity aimed at reversing developmental
Neuronascent Appoints New Board Member | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer's Disease | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362 June 28, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc., announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Assoc … oss. Completion of Phase 1a in healthy aged subjects was supported by NIA under award number R01AG056561 demonstrating that there were no safety findings due to oral NNI-362 administration and an early demonstration of brain marker changes. About NNI-362 In aging patients, endogenous neuron regeneration is diminished. This diminution is exacerbated in patients suffering from neurodegeneration, for example Alzheimer’s patients. NNI-362, Neuronascent’s patented, first-in-class, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
#bio2025 #biotechinnovation #drugdevelopment #alzheimers #parkinsons #fragilex #caninecognitivedysfunction #partnering #lifesciences #bostonbiotech | Neuronascent, Inc LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree
Contact Us - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Contact Us NeuroNascent, Inc. Corporate Headquarters 6030 Day Break Circle A150 – PMB244 Clarksville, MD 21029 Neuronascent is a privately-held corporation. For business development or general inquiries, please email us at [email protected]. For accredited investors please contact Investor Relations at [email protected] . © 2026 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark Home About Us ▼ Founder’s Message Management Team Directors and Advisors Collaborator
Biotechnology Company Deals With Other Biotechnology Companies: Nov. 1 - Dec. 23, 2009 + | Bioworld | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease March 30, 2022 | 4 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerativ … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuronascent Announces the Expansion of its Board of Directors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Re … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Neuronascent Announces the Expansion of its Board of Directors April 12, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer Leahy, Ph.D., MBA, to its Board of Dir … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NeuroNascent, Inc. Announces License of Its Patented Animal Cells to Lifeline Cell Technology, LLC - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and G … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business NeuroNascent, Inc. Announces License of Its Patented Animal Cells to Lifeline Cell Technology, LLC May 29, 2007 | 2 min read Twitter LinkedIn Facebook Email Print CLARKSVILLE, Md., May 25 /PRNewswire/ -- Neuronascent, Inc. ( http://www.neuronascent.com ) announced today the license of animal … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer's Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer’s Disease September 29, 2021 | 4 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc., a clinical-stage pharmaceutical company developing first-in-class neuron generating therapeutics, … r's disease. This placebo-controlled, randomized trial was fully supported by a grant from the National Institute on Aging (NIA), part of the National Institutes of Health. The primary goal of this trial was to assess the safety and tolerability of oral NNI-362 in a healthy aged population of subjects 50-72 years of age. In topline results, oral liquid-formulated NNI-362 administration in single and multiple ascending doses never reached a Maximum Tolerated Dose (MTD). NNI-36 … n , PhD. The research reported in this press release was supported by NIA under award number R01AG056561. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. About NNI-362 NNI-362 is Neuronascent's lead, patented, new chemical entity developed to reverse age-related disorders by producing new neurons to replace those lost due to chronic neurodegenerative disorders. NNI-362's abilit … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NeuroNascent, Inc. Announces Issuance Of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital NeuroNascent, Inc. Announces Issuance Of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate January 29, 2014 | 2 min read Twitter LinkedIn Facebook Email Print CLARKSVILLE, MD--(Marketwired - January 29, 2014) - Highlighted Links http://www.neuronascent.com Neuronascent, Inc. a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NeuroNascent, Inc. Issued US Patent for Neurogenesis, Therapeutic Candidates - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital NeuroNascent, Inc. Issued US Patent for Neurogenesis, Therapeutic Candidates October 27, 2011 | 2 min read Twitter LinkedIn Facebook Email Print CLARKSVILLE, MD--(Marketwire - October 26, 2011) - Highlighted Links http://www.neuronascent.com Neuronascent, Inc. ( www.neuronascent.com ) announced today t … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Identifying Missing Links - and Why Certain Drugs Don't Work - in Alzhiemer's - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Identifying Missing Links - and Why Certain Drugs Don’t Work - in Alzhiemer’s March 30, 2022 | 5 min read | Mark Terry Twitter LinkedIn Facebook Email Print simonkr_Getty Images A team at the University of California, San Diego developed a drug screening method to help de … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuronascent Announces Collaboration With ChemRar For Characterization Of Developmental Pathway Inhibitors Using Neuronascent's Neurogenesis Platform Get more Drug Discovery insight with our FREE newsletter sign me up Log In or Subscribe Topics Bioinformatics Regulatory Target Research Innovation Preclinical Entrepreneurship Partners & Suppliers Research Partners Cellular Models Target Discovery Assay & Screening Imaging & Translational Models Analytical Characterization Watch Now Drug Discovery Online Live News | November 4, 2009 Neuronascent Announces Collaboration With ChemRar F
Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Neuronascent Announces Progress for Lead Candidate NNI-362: Publication of Phase 1a Clinical Trial Results and FDA Grants Waiver of Fee for Canine Cognitive Disorder 2025 Submissions August 13, 2025 | 3 min read Twitter LinkedIn Facebook Email Print BALTIMORE., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Neuronasce … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome May 24, 2022 | 3 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc. announced that the US Food and Drug Administration granted rare pediatric designation for NNI-351 for Fragile … entially reverse FXS behavioral deficits in young individuals. With a marketing application for NNI-351 for young FXS patients, Neuronascent as sponsor will request an award of a rare pediatric disease priority voucher . The FDA’s Rare Pediatric Disease Priority Voucher Program is designed to incentivize companies to develop novel therapies to treat rare disorders of under 200,000 individuals and that primarily afflict those under the age of 18. The priority review voucher co … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal January 20, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc., a privately-held neuron regeneration therapeutics company, announce … for mild to moderate Alzheimer’s disease (AD), which is supported by a NIA R01 grant in healthy aged volunteers. The short report in the Stem Cell Research & Therapy journal https://doi.org/10.1186/s13287-020-02126-3 entitled “Novel pharmacotherapy: NNI-362, an allosteric p70S6 kinase stimulator, reverses cognitive and neural regenerative deficits in models of aging and disease”, describes the phenotypic screen used by Neuronascent to discover NNI-362 and details the in … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuronascent Secures Financing For Development Of Its Alzheimer's Therapeutic - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Canc … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search BioCapital Neuronascent Secures Financing For Development Of Its Alzheimer’s Therapeutic April 7, 2015 | 2 min read Twitter LinkedIn Facebook Email Print CLARKSVILLE, MD--(Marketwired - April 06, 2015) - Highlighted Links http://www.neuronascent.com Neuronascent, a biopharmaceutical company developing non-invasiv … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business J … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News FDA Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer’s Disease May 9, 2019 | 6 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug … Food and Drug Administration has cleared the Company’s Investigational New Drug application for its proprietary oral therapeutic, NNI-362, to proceed into Phase 1 clinical testing in a healthy aged population. MARYLAND, May 7th, 2019 (West GlobeNewswire) -- Neuronascent Inc. , a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its p … ety, tolerability and pharmacokinetic measures is funded by a $2.25 million RO1 grant awarded to Neuronascent by National Institute on Aging (NIA), National Institutes of Health. This NIA support of the IND- enabling and Phase 1 studies is part of the Institute’s expanded drive to support novel therapies for AD and promote the development of disease-modifying therapies, which, to date, have proved elusive. R. Scott Turner, MD, PhD, Director of the Memory Disorders Program at … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
NeuroNascent, Inc. - Product Pipeline Review - 2014 By Radiant Insights What's this ? Login Register Media agencies Submit a press release Press releases Services Radiant Insights NeuroNascent, Inc. - Product Pipeline Review - 2014 By Radiant Insights Radiant Insights - Friday, May 22, 2015. Submitted by MarketResearchri . NeuroNascent, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'NeuroNascent, Inc. - Product Pipeline Review - 2014', provides an overview of the NeuroNascent, Inc.'s pharmaceutical research and development focus. This report provides comprehensive info
Neuronascent Funding: How Much Did They Raise & Key Investors Products Product ZoomInfo Copilot AI sales agent GTM Workspace AI workspace for smarter GTM GTM Studio Build and run GTM workflows triggered by buying signals ZoomInfo MCP Connect your AI to verified B2B data Sales Company and contact database Marketing Actionable ABM platform Talent Source the best and brightest Operations Lead routing and data quality Data as a Service ZoomInfo data for your GTM systems Platform Cloud partners Ready, set, integrate Platform overview Connect industry-leading data across your entire tech stack M
Neuronascent Issued Patent for Potential Therapies to Treat Alzheimer's Skip to content Newsletter Search Search for: Search Toggle navigation Search for: Search About Alzheimer's disease Toggle menu: About Alzheimer's disease What is Alzheimer’s disease? Causes Symptoms Diagnosis Pseudobulbar affect Early-onset Alzheimer's Treatments Approved treatments Experimental treatments Non-drug treatments Deep brain stimulation Repetitive transcranial magnetic stimulation Living With Toggle menu: Living With Living with Alzheimer’s disease Community Toggle menu: Community Columns Treading Dark Wa … wships and has won the Portuguese Immunology Society Best Paper and Best Poster award in 2009 and 2010, as well as the CESPU International Research Award in 2010. After leaving the lab to pursue a career in science communication, she served as the director of science communication at iMM Lisbon. Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment Recent Posts Awareness month event has ne
NNI-362 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 18 Apr 2026 NNI-362 Last update 18 Apr 2026 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms NNI 362 Target NGFB Action stimulants Mechanism NGFB stimulants(Beta-nerve growth factor stimulants) Therapeutic Areas Nervous System Diseases Congenital Disorders Other Diseases Active Indication Huntington Disease Inactive Indication Alzheimer Disease Ori … sociated with NNI-362 22 Aug 2023 · www.biospace.com Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investiga … th the CEO, Dr. Judith Kelleher-Andersson being the principal investigator. The grant, titled “Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial,” will allow for the longer-term assessment of Neuronascent’s investigational drug, in a proof-of-concept clinical trial. Neuronascent discovered experimental therapeutic NNI-362 through a novel screening program aimed at identifying small … te short term GLP safety testing for submission of the Investigational New Drug application, and secondly for the completion of the Phase 1a clinical safety trial in healthy aged population. Alzheimer’s is a disease of aging, the greatest risk-factor, and even with new therapies aimed at slowing early progression into Alzheimer’s disease, there remains a great unmet need for a disease-modifying treatment for the 6.7 million patients, in the United States alone, already suffer … isease at the next stage of disease progression from pre-AD to severe AD.” This grant award should allow the further long-term safety testing and further GMP manufacture of NNI-362 required before running a critical trial to assess whether NNI-362 will indeed address the next stage of AD disease progression by halting and potentially reversing di
New Jersey Employers | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas US Biotech Employers Displaying 5351 - 5400 of 8430 biotech employer locations Filter the data by: Select State - Any - Alabama Alaska American Samoa Arizona Arkansas Armed Forces (AA) Armed Forces (AE) Armed Forces (AP) California Colorado Connecticut Delaware District of Columbia Florida
%PDF-1.3 %�쏢 5 0 obj > stream x��]Ys ��~��5ۡ.�}�ӎ���1�e:�A�C�x��l����� ��� ��WG7%�"�* �Dޙ@����4_���}hoO~��Z]�O����?��:��$���,��>���ߟ���*���^�]�$݇dU7Q�4ɪJ�(IWg�'oN�_WQ��yrz��������q���8������>��� ���*e���� �U) ֛��J5��� �I�~y��Z���!�ꍖ�;��� �8Mgw�z�!B R�.�]�����O3�Q��Qv�q� ;�c��8� �x������0�;%�Ű�q:j�M!N���-T��,h��mȳvt@J �]��f�_R�rN�ghm)غa�)L�e�רCm�_�D�ٵǍg�v�% @e@���"c�K�M�ni~.�!?��JG�z��.���F�I�w��e� �5�,b�JY�Gb�h�gsx������+x�Q�d�V9�K��zD��@����N Џ[m:��D� ���W^rB`ꅩ�G��p�"mVL�e�� �V �� 8:�n�A>��4�q˶�iŌt�D9芶�·�~c�Q$6���E� /z��T$�Ǫ�aHVa �� >^d���V�O�@��(��
Neuronascent | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Neuronascent Website: Neuronascent Business Area(s) Small Molecules Stem Cells Description Small molecules, stem cells Company Location(s) Clarksville , MD United States body Sign up for news Contact Us Add an Employer About the Site Site's Purpose and Use Articles People in Biotech Biotech C
%PDF-1.5 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 14 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S>> endobj 4 0 obj > stream x��[Ys�~ߪ�(�d���3�5���r�Ď�+?�y͡Q�D���ί��E5���%���n��u�{y�����R�Z�l߾�"3�KQ�4S�(�:m*q���M&��חo��0�fs�v���զ=$�7_�}��������eZ�!� fb0͍��h�}r�f���Y��䢘uI={L.�پ{J.����>)g]+��^L����YZ�L����1���ۤ�-F&qߊ�E53��7Iv���y�/ �oAJ��-�U���w��M���b�����l@�ծ� ��_a�)�ZW��� �~~��T'�Rʴ�Ӯ @kKX���d�xNd5�����5_�~���7�w�#��# ���^����P���l�![��Ӭ��z�e�rqV UeÙ��T��X�F+��'#� .�h#�\�=�����q6�)��B�+����^}�N�Y
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease August 22, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Neuronascent Inc., a privately-held neuron regeneration therapeutics company, announced that … tics company, announced that the National Institute of Aging, has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investigator. ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc. , a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal inves … th the CEO, Dr. Judith Kelleher-Andersson being the principal investigator. The grant, titled “Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial,” will allow for the longer-term assessment of Neuronascent’s investigational drug, in a proof-of-concept clinical trial. Neuronascent discovered experimental therapeutic NNI-362 through a novel screening program aimed at identifying small … te short term GLP safety testing for submission of the Investigational New Drug application, and secondly for the completion of the Phase 1a clinical safety trial in healthy aged population. Alzheimer’s is a disease of aging, the greatest risk-factor, and even with new therapies aimed at slowing early progression into Alzheimer’s disease, there r
Onyx Completes API project with Neuronascent - European Pharmaceutical Manufacturer Skip to main content Search Talk to us | Media Portfolio | Latest Issue | My Account linkedin RSS Home Pharma Manufacturing News + Latest Pharmaceutical Manufacturing News Manufacturing News Packaging News Sustainability News Logistics & Distribution News Drug Delivery News Biopharma News Digital Health in Pharma News Regulatory News Finance & Investment News Pharmaceutical Insights + Latest Pharmaceutical Insights Manufacturing Insights Packaging Insights Sustainability Insights Logistics & Distrib … ronascent and were able to deliver their project on time despite a pretty tight deadline. “We look forward to potentially having the opportunity to work with them on the next phase of the project, which would involve the GMP production of API to support clinical trials.” Onyx Scientific’s UK-based labs deal with challenging chemistry to deliver early stage programmes and is then able to scale-up, tech transfer and increase project efficiency using its
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
NeuroNascent - HQ | The Org Platform Enrich Pricing Log in Sign up NeuroNascent Offices HQ Unverified HQ 0 people · 0 jobs NeuroNascent's headquarters in Clarksville, MD, United States Office location People ( 0 ) No people in this office Jobs ( 0 ) No jobs in this office Other offices View all offices No other offices Company About Contact Blog Business Solutions Trust Pricing Directory Companies People Features Employer Branding Professional Networking Job Discovery Social © 2026 Orgio, Inc. Terms Privacy Do not sell my info
Veterinary Medicine Program - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Veterinary Medicine Program Neuronascent (NNI) Receives IACUC Approval to Begin Treatment of Aged Dogs with Probable Canine Cognitive Dysfunction (CCD) in Fairbanks, Alaska Using NNI’s Novel Neuron Regenerative Therapy – Cajuvenate Neuronascent and the University of Alaska – Fairbanks (UAF) are working together to test and treat older sled dogs and canine pets that have probable Canine Cognitive Dysfunction (CCD) a similar disorder to Alzheimer’s disease observed in humans. The study has be … Chemistry, Manufacturing and Controls sections have already been completed. New Grant To Halt and Reverse Dementia in Dogs First CHICAGO, Jan. 8, 2026 — Alzheimer’s Association Part the Cloud today announced more than $11 million in new investments to advance transformational therapeutics for Alzheimer’s and other diseases that cause dementia. Part the Cloud is a global movement with a recognized name and impact that has generated more than $90 million and funded 83 clinical … ; Each of the 11 grants is for approximately $1 million. The new Part the Cloud grant awardees are: Translational Research Grant Program Glenn Larsen, Ph.D., Aquinnah Pharmaceuticals, Inc. Tauopathy Therapeutic AQV-8741: A Phase I Study. Terry Goldberg, Ph.D., Research Foundation for Mental Hygiene, Inc. at New York State Psychiatric Institute. Vortioxetine to improve synaptic connectivity. Luis Oskar Soto-Rojas, Ph.D., National Autonomous University of Mexico. Creatine-Augme
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
NeuroNascent, Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Even … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search NeuroNascent, Inc. NEWS JOBS NEWS Drug Development Identifying Missing Links - and Why Certain Drugs Don’t Work - in Alzhiemer’s A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons. March 30, 2022 &nb … d · Mark Terry FDA Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer’s Disease Neuronascent Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for its proprietary oral therapeutic, NNI-362, to proceed into Phase 1 clinical testing in a healthy aged population. May 9, 2019 · 6 min read IN THE PRESS Press Releases Neuronas … 2025 · 3 min read Drug Development Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease August 22, 2023 · 3 min read BioCapital Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362 June 28, 2023 · 3 min read BioCapital Neuronascent Announces the Expansion of its Board of Directors Ap … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NeuroNascent, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 29 Aug 2025 NeuroNascent, Inc. Holding Company | 2004 | Maryland, United States | < 10 | www.neuronascent.com Holding Company | 2004 | Maryland, United States | < 10 | www.neuronascent.com Last update 29 Aug 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Other Diseases Congenital Disorders Small molecule drug Disease domain score A glimpse into the focuse … th NeuroNascent, Inc. 22 Aug 2023 · www.biospace.com Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investiga … th the CEO, Dr. Judith Kelleher-Andersson being the principal investigator. The grant, titled “Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial,” will allow for the longer-term assessment of Neuronascent’s investigational drug, in a proof-of-concept clinical trial. Neuronascent discovered experimental therapeutic NNI-362 through a novel screening program aimed at identifying small … te short term GLP safety testing for submission of the Investigational New Drug application, and secondly for the completion of the Phase 1a clinical safety trial in healthy aged population. Alzheimer’s is a disease of aging, the greatest risk-factor, and even with new therapies aimed at slowing early progression into Alzheimer’s disease, there remains a great unmet need for a disease-modifying treatment for the 6.7 million patients, in the United States alone, already suffer … isease at the next stage of disease progression from pre-AD to severe AD.” This grant award should allow the further long-term safety testing and further GMP manufacture of NNI-362 required before running a critical trial to assess whether NNI-362 will indeed address the next stage of AD disease progression by halting and potentially reversing di
%PDF-1.5 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S>> endobj 4 0 obj > stream x��Z�o�6�����h�*R� @` �6����^7����ǖcam)g�����y�z�\{��8��3���o ����7��K��x\�}#E�I�� ���, �X ov�.ѓ�3C�+�T�'`8F��� >��u\��ӣ�D��/0�="������ahd�;�L����F����g�i=�� ����D��� I� �W)������H���o�R^[rB��|�]��p�2� Ð���n$w>#�:#�3u����n����y:y���[�m��څ$�w��Y� �#��uʛ��5�Ŏ�� ��k�۸c���pI����QiR $�g�yȋV ��Y2� �=�/� �r#� ��: d:X�Kؙ���Vf�N���-����|�9ڇVH�Y�5Y����y�Q�M+]��w�O������Urm�ϰ 9��K
Neuronascent Appoints New Board Member --> Accessibility: Skip TopNav Neuronascent Appoints New Board Member April 12, 2017 06:30 ET | Source: Neuronascent, Inc. Neuronascent, Inc. CLARKSVILLE, MD --(Marketwired - April 12, 2017) - Neuronascent, Inc., a neuro-pharmaceutical company developing proprietary therapeutics for Alzheimer's disease, Parkinson's disease, and psychiatric disorders, today announced the appointment of Dr. Kenneth Narducy to its Board of Directors, effective immediately. Dr. Narducy continues his role in the biotech start-up community handling operations at Eravon T
Neurogenesis & Neuron Regeneration - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Neurogenesis & Neuron Regeneration New neurons form in the brain from neuronal progenitor cells well into adulthood, but only in two distinct regions of the brain. The hippocampus, an area critical for learning and memory, and the subventricular zone each have a significant neuronal progenitor cell niche. For a neuronal progenitor cell to transform into a mature and functioning neuron involves a number of steps (see figure below). The first step of this multi-step process in
Neuronascent plans Phase II Parkinson’s disease trial with neurorestorative drug Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filin … . Additionally, the company is hoping to file an Investigational New Drug (IND) application for NNI-362 of Parkinson’s disease this year, she added. Judith Kelleher-Andersson, CEO of Neuronascent In September 2021, the company released positive topline results from the Phase Ia NNI-362 study for Alzheimer’s disease. In the trial, the drug did not reach a maximum tolerated dose and was reported to have led to no serious adverse events and no dose-dependent adverse events. Neur
NNI-351 — Grokipedia Search ⌘K Suggest Edit Sign in Sign in Medical uses Potential indications Clinical development status Pharmacology Mechanism of action Pharmacokinetics Chemistry Chemical structure Properties and synthesis Development and research Discovery and preclinical studies Regulatory milestones Society and culture Commercial aspects Naming and identifiers References Fact-checked by Grok 5 months ago NNI-351 Ara Eve Leo Sal 1x NNI-351 is an experimental small-molecule drug candidate developed by NeuroNascent, Inc., a clinical-stage biotechnology company focused on regenerative thera … velopment, with NeuroNascent planning to file an Investigational New Drug (IND) application to advance to human clinical trials; its pipeline also explores applications in depression, post-traumatic stress disorder (PTSD), and other neurodegenerative conditions. [6] These designations underscore NNI-351's potential as a pioneering regenerative approach in neurodevelopmental medicine, supported in part by organizations like FRAXA Research Foundation. [1] Medical uses Potential … f funding is obtained, the company intended to file an Investigational New Drug application by late 2023 and commence the trial in early 2024; otherwise, options such as licensing or collaborations may be pursued. Phase II trials are planned for Parkinson's disease following successful Phase I completion. No updates on these plans have been reported. [9] [6] Preclinical studies in animal models of developmental disorders, including Fragile X syndrome and Down syndrome, have d … ity review voucher upon FDA approval, which can expedite review of another drug application, and potential fee waivers to support development for rare pediatric conditions. [18] Shortly thereafter, in June 2022, the FDA awarded Orphan Drug Designation to NNI-351 for Fragile X syndrome, further acknowledging its role in treating a rare disease with limited available therapies. [19] This status offers benefits including seven years of market exclusivity upon approval, tax credi … tion NNI-351 for potential progression toward an Investigational New Drug (IND) application and Phase I clinical trials, contingent on ongoing preclinical advancements and funding. [1] Society and culture Commercial aspects NNI-351 is being developed by Neuronascent, Inc., a biotechnology company focused on neurorestorative therapies aimed at pro
Neuronascent, Inc. | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Neuronascent, Inc. Neuronascent is a biotechnology company focused on generating new neurons and reversing neurological disorders. It develops small-molecule therapeutics aimed at neurogenesis and neuron regeneration, with ongoing R&D programs targeting diseases such as Alzheimer’s and Parkinson’s. The company is led by a team of experienced scientists and industry professionals dedicated to advancing neuroregenerative therapies. Industries biotechnology … Canine Cognitive Disorder (CCD) in older dogs. 2023 Neuronascent announces NIA grant award for NNI-362 to reach Phase 2 clinical trials for Alzheimer’s disease. 2023 Longevity Technology News recognizes significant advancement of NNI-362 for Alzheimer’s treatment. 2023 Neuronascent to present new Parkinson’s model data at AAIC 2023 for NNI-362. 2023 CEO to present on therapy-induced neuron genesis at the World Orphan Drug Congress 2023. 2022 Neuronascent to present further N … ghting potential for therapies to improve healthspan. 2019 FDA clearance of IND application for NNI-362. 2018 CEO/Founder invited to present on neuron regeneration at World Alliance Forum. 2018 NIH grant awarded to develop regenerative therapeutic for Alzheimer’s. Reversing neurodegeneration with new neurons and clinical trials An article on NeuroNascent’s clinical-stage drug, NNI-362, and its potential to reverse neurodegenerative diseases such as Alzheimer’s and Parkinson’s
Home - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders © 2026 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and inv
Kenneth Narducy, Ph.D., MBA - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Kenneth Narducy, Ph.D., MBA Acting COO, Director Kenneth W Narducy, PhD, MBA, has spent more than 30 years in research and development at biomedical companies (including Abbott and Schering-Plough and the last 20 years with young biomedical companies). Three of the pharma companies in which he was a senior executive were acquired (Oculex by Allergan for $230 million, Centaur by Renovis [now Evotec] for $47 million, and St Charles Pharmaceuticals by Colby Pharmaceutical Company). Dr Narducy
Discovery of neurogenic, Alzheimer's disease therapeutics Discovery of neurogenic, Alzheimer's disease therapeutics Curr Alzheimer Res . 2006 Feb;3(1):55-62. doi: 10.2174/156720506775697179. Author Judith Kelleher-Andersson 1 Affiliation 1 Dept. of Neurobiology, Neuronascent Inc., 6030 DayBreak Circle, Suite A150 PMB 244, Clarksville, MD 21029, USA. [email protected] PMID: 16472204 DOI: 10.2174/156720506775697179 Abstract Many researchers have questioned whether new potential therapies aimed at reversing Alzheimer's disease (AD) are indeed scientifically feasible. A n
Neuronascent Inc. | B-G Andersson – Astronomer Skip to content B-G Andersson – Astronomer Search Primary Menu Contact På Svenska Search for: Neuronascent Inc. My wife, Judith Kelleher-Andersson’s company Neuronascent, Inc. is developing small molecule therapeutics for neurodegenerate disorders such as Alzheimer’s Decease, Parkinson’s Decease and Down Syndrome. B-G’s Home Page Dust Grain Alignment in the Interstellar Medium. PUFFINS Publications and Presentations The long and the short of it Meetings, White Papers, etc. SOFIA Staff Science Symposia Science Te
Judith Kelleher-Andersson, Ph.D. - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Judith Kelleher-Andersson, Ph.D. President and Chief Executive Officer (CEO), Director Dr. Kelleher-Andersson has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. Prior to founding Neuronascent, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Cortex Pharmaceuticals, Inc. She headed the Alzheimer’s disease program in collaboration with Astra-Zeneca while at Cen … uri-Columbia and completed post-graduate work at UCLA with a Mental Retardation Fellowship and at University of California, San Francisco in the Neurology Dept. Back to Directors and Advisors © 2026 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark Home About Us ▼ Founder’s Message Management Team Directors and Advisors Collaborators Memberships Technology ▼ Neurogenesis & Neuron Regeneration Drug Discovery Intellectual Property R&D Programs
Directors and Advisors - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Directors and Advisors Directors Judith Kelleher-Andersson, Ph.D. – Read Bio Kathleen L. Mattis, MBA – Read Bio Robin Oegerle, MFA – Read Bio Maurice Gagnon – Read Bio Kenneth Narducy, Ph.D., MBA – Read Bio Scientific Advisory Board Scott Turner, PhD, M.D. – Read Bio Vice Chair for Clinical Research, Professor of Neurology, and Director of the Memory Disorders Program at Georgetown University David A. Greenburg, M.D. Ph.D. – Read Bio Vice President for S
Joel S. Ross, M.D., FACP, AGSF, CMD - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Joel S. Ross, M.D., FACP, AGSF, CMD Dr. Ross is the Founder, CEO, Primary Care Geriatrician and Principal Investigator at the Memory Enhancement Center of America in Long Branch, New Jersey. Dr. Ross served as Principal Investigator or Sub-investigator on nearly every Alzheimer’s disease drug in clinical trials since 1994, including Ondansetron, Cognex, Donepezil, Exelon, Memantine and, most recently, Alzhemed (Neurochem) and ELN116727 (ELAN). He has a number of hospital appoi … m Downstate Medical Center, Brooklyn, New York. He completed his internship and residency at Nassau County Medical Center East Meadow, New York, where he then became chief resident. He is certified in Geriatric Medicine and Internal Medicine and by the National Board of Medical Examiners. Back to Directors and Advisors © 2026 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark Home About Us ▼ Founder’s Message Management Team Directors and Advisors Colla
Pipeline - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Pipeline Pipeline Alzheimer’s Disease Parkinson’s Disease Developmental Delay Veterinary Medicine Program © 2026 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark Home About Us ▼ Founder’s Message Management Team Directors and Advisors Collaborators Memberships Technology ▼ Neurogenesis & Neuron Regeneration Drug Discovery Intellectual Property R&D Programs ▼ Pipeline Alzheimer’s Disease Parkinson’s Disease Developmental Delay Veterinary Medicine Progr
About Us - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders About Us Founder’s Message Management Team Directors and Advisors Collaborators Memberships © 2026 NeuroNascent, Inc. - All Rights Reserved - Website by Teramark Home About Us ▼ Founder’s Message Management Team Directors and Advisors Collaborators Memberships Technology ▼ Neurogenesis & Neuron Regeneration Drug Discovery Intellectual Property R&D Programs ▼ Pipeline Alzheimer’s Disease Parkinson’s Disease Developmental Delay Veterinary Medicine Program News & Event
Drug Discovery - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Drug Discovery In order to discover a therapeutic that promotes neurogenesis, Neuronascent’s scientists initially concluded that two essential criteria of a central nervous system (CNS) drug are: a small-molecule that can easily cross into the brain from the blood stream and a molecule that is orally administered. The former requirement stems from the fact that the blood vessels in the brain are surrounded by a “blood-brain barrier” which protects the brain from blood borne diseases and path
Founder's Message - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Founder’s Message Judith Kelleher-Andersson, Ph.D. Founder, President and Chief Executive Officer (CEO) “A therapy that is only neuroprotective will never be sufficient to halt or reverse neurodegenerative disease progression”. I came to this realization after working in the neuroscience field for over 20 years as a graduate student, as a post-graduate fellow and after working at three biotech companies, where I directed the discovery of therapeutics aimed at Alzheimer’s … crosses the barrier between blood and brain, then the above concerns should not apply. An oral medicine can take advantage of endogenous neuronal progenitors, found in select niches of the adult/aging brain. Neuronal progenitors are naturally pushed to become new neurons, to respond to injury. We now believe, there are indeed ways to achieve a heightened response to the diseased brain’s own “compensatory response” to injury. In other words, the brain itself, even under … ged subjects as we showed in animals (National Institute of Aging 1R01 AG056561 grant awarded). This should allow for further testing in Alzheimer’s patients, with the first neuron regenerative therapy, NNI-362. With a further NIA grant award and potential investment dollars, Neuronascent aims to test NNI-362 in both mild to moderate Alzheimer’s patients and in early Parkinson’s patients, to reverse disease progression. Neuronascent is a small corporation, that we belie
Management Team - Neuronascent, Inc. Generating New Neurons Reversing Neurological Disorders Management Team Judith Kelleher-Andersson, Ph.D. President and Chief Executive Officer (CEO), Director Dr. Kelleher-Andersson has over twenty years of experience developing small-molecule, central nervous system therapeutics in the biotechnology industry. Prior to founding Neuronascent, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Cortex Pharmaceuticals, Inc. She headed the Alzheimer’s disease program in collaboration with Astra-Zeneca while at Cent … uri-Columbia and completed post-graduate work at UCLA with a Mental Retardation Fellowship and at University of California, San Francisco in the Neurology Dept. Kenneth Narducy, Ph.D., MBA Acting COO, Director Kenneth W Narducy, PhD, MBA, has spent more than 30 years in research and development at biomedical companies (including Abbott and Schering-Plough and the last 20 years with young biomedical companies). Three of the pharma companies in which he was a senior executive w